Quick Dispatch:
Your tirzepatide surpass-5 Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass-5 Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial ships.
Need Help?
Questions about tirzepatide surpass-5 Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass-5 Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial in your area.
Tirzepatide reduces albuminuria among adults with type 2 diabetes in SURPASS trials
25.19
![Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1](https://www.researchgate.net/publication/363201315/figure/fig3/AS:11431281082605778@1662084799021/Efficacy-of-tirzepatide-in-phase-2-GPGB-14-and-phase-3-SURPASS-1-to-5-15-19.png)
Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1
27.81
Media Centre
29.37
Diabetes Distilled: “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life
26.83
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics | Diabetes Therapy
24.97
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
23.38
Tirzepatide Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program-CliniExpert
21.36
